A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells
Crossref DOI link: https://doi.org/10.1186/s12885-017-3504-1
Published Online: 2017-08-11
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Senhaji Mouhri, Zhor
Goodfellow, Elliot
Jean-Claude, Bertrand http://orcid.org/0000-0002-4312-6485
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-130363)
